BARDA in coordination with Department of the Air Force’s Acquisition COVID-19 Task Force (DAF ACT) has awarded an undefinitized contract action (UCA) to Ortho Clinical Diagnostics. This UCA will lead to a firm fixed price commercial contract of $53.7 million supporting the COVID-19 response and will increase production capacity of U.S. COVID-19 antibody and antigen test kit assays as well as test analyzers.
The industrial base expansion effort, with a planned final value of $53.7 million, will allow Ortho Clinical Diagnostics to order long lead equipment to establish a domestic production capability of VITROS Systems and SARS-CoV-2 Antigen and Antibody Tests at its Rochester, New York Global Center of Excellence facility for R&D.
At the completion of this expansion effort, Ortho Clinical Diagnostics will increase its production capacity from 1.8 million tests per month to 6.7 million tests per month by April 2022.
The DOD’s Defense Assisted Acquisition (DA2) Cell led this effort in coordination with the Department of the Air Force’s Acquisition COVID-19 Task Force (DAF ACT). BARDA funded this contract through the Health Care Enhancement Act (HCEA) to enable and support domestic industrial base expansion for critical medical resources.